Taysha Gene Therapies (NASDAQ:TSHA) Insider Sukumar Nagendran Sells 200,000 Shares

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) insider Sukumar Nagendran sold 200,000 shares of the stock in a transaction dated Friday, April 10th. The stock was sold at an average price of $4.46, for a total value of $892,000.00. Following the transaction, the insider owned 1,136,410 shares of the company’s stock, valued at approximately $5,068,388.60. This trade represents a 14.97% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Sukumar Nagendran also recently made the following trade(s):

• On Monday, January 26th, Sukumar Nagendran sold 26,918 shares of Taysha Gene Therapies stock. The shares were sold at an average price of $4.61, for a total value of $124,091.98.
• On Friday, January 23rd, Sukumar Nagendran sold 89,132 shares of Taysha Gene Therapies stock. The shares were sold at an average price of $4.75, for a total value of $423,377.00.

Taysha Gene Therapies Stock Down 1.6%

TSHA stock opened at $4.42 on Tuesday. The company has a debt-to-equity ratio of 0.20, a current ratio of 12.23 and a quick ratio of 12.23. The stock has a market capitalization of $1.27 billion, a P/E ratio of -13.00 and a beta of 1.10. Taysha Gene Therapies, Inc. has a fifty-two week low of $1.13 and a fifty-two week high of $6.02. The business has a 50-day moving average of $4.53 and a 200-day moving average of $4.72.

Taysha Gene Therapies (NASDAQ:TSHA) last announced its earnings results on Thursday, March 19th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.03. The firm had revenue of $5.49 million during the quarter, compared to analyst estimates of $1.89 million. On average, sell-side analysts anticipate that Taysha Gene Therapies, Inc. will post -0.35 earnings per share for the current fiscal year.

Analysts Set New Price Targets

TSHA has been the topic of a number of research reports. Truist Financial raised shares of Taysha Gene Therapies to a “strong-buy” rating in a research report on Wednesday, March 25th. Wells Fargo & Company raised their target price on shares of Taysha Gene Therapies from $8.00 to $11.00 and gave the company an “overweight” rating in a research report on Monday, January 5th. Chardan Capital reiterated a “buy” rating and issued a $12.00 price target on shares of Taysha Gene Therapies in a research note on Thursday, March 19th. Wall Street Zen raised shares of Taysha Gene Therapies from a “sell” rating to a “hold” rating in a research report on Saturday, March 21st. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Taysha Gene Therapies in a research note on Friday, March 27th. Two research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $11.64.

Institutional Investors Weigh In On Taysha Gene Therapies

Large investors have recently made changes to their positions in the stock. Vestal Point Capital LP grew its stake in shares of Taysha Gene Therapies by 150.0% in the fourth quarter. Vestal Point Capital LP now owns 13,750,000 shares of the company’s stock valued at $75,625,000 after buying an additional 8,250,000 shares in the last quarter. Goldman Sachs Group Inc. lifted its stake in Taysha Gene Therapies by 2.3% in the fourth quarter. Goldman Sachs Group Inc. now owns 13,692,739 shares of the company’s stock valued at $75,310,000 after acquiring an additional 309,031 shares during the last quarter. Vanguard Group Inc. lifted its stake in Taysha Gene Therapies by 3.3% in the fourth quarter. Vanguard Group Inc. now owns 13,267,805 shares of the company’s stock valued at $72,973,000 after acquiring an additional 418,192 shares during the last quarter. Octagon Capital Advisors LP grew its position in shares of Taysha Gene Therapies by 17.7% in the 2nd quarter. Octagon Capital Advisors LP now owns 12,592,500 shares of the company’s stock valued at $29,089,000 after acquiring an additional 1,892,500 shares during the period. Finally, State Street Corp grew its position in shares of Taysha Gene Therapies by 49.1% in the 4th quarter. State Street Corp now owns 10,790,084 shares of the company’s stock valued at $59,345,000 after acquiring an additional 3,553,619 shares during the period. Institutional investors and hedge funds own 77.70% of the company’s stock.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.